{"id":"NCT02342886","sponsor":"Global Alliance for TB Drug Development","briefTitle":"Shortening Treatment by Advancing Novel Drugs","officialTitle":"A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02","primaryCompletion":"2018-01","completion":"2018-05","firstPosted":"2015-01-21","resultsPosted":"2019-03-26","lastUpdate":"2019-03-26"},"enrollment":284,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tuberculosis, Pulmonary, Drug Sensitive","Tuberculosis, Pulmonary, Multi Drug-resistant"],"interventions":[{"type":"DRUG","name":"Moxifloxacin","otherNames":["BAY 12-8039","Avelox","Avalon","Avelon"]},{"type":"DRUG","name":"PA-824","otherNames":[]},{"type":"DRUG","name":"Pyrazinamide","otherNames":[]},{"type":"DRUG","name":"HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)","otherNames":["Rifafour e-275"]},{"type":"DRUG","name":"HR (rifampicin plus isoniazid combination tablets)","otherNames":[]}],"arms":[{"label":"MDR-TB","type":"EXPERIMENTAL"},{"label":"DS-TB (HRZE), HR","type":"ACTIVE_COMPARATOR"},{"label":"DS-TB PA-824 200mg 26 weeks","type":"EXPERIMENTAL"},{"label":"DS-TB PA-824 200mg 17 weeks","type":"EXPERIMENTAL"},{"label":"DS-TB PA-824 100mg 17 weeks","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy, safety and tolerability of a combination of moxifloxacin, PA-824, and pyrazinamide treatments with varying doses and treatment lengths from 4 to 6 months in subjects with drug-sensitive (DS) pulmonary TB compared to standard HRZE treatment.\n\nThis study will also assess the efficacy, safety and tolerability of a combination of moxifloxacin, PA-824, and pyrazinamide treatments after 6 months of treatment in subjects with multi drug-resistant (MDR) pulmonary TB compared to a combination of moxifloxacin, PA-824, and pyrazinamide treatments in DS-TB subjects.","primaryOutcome":{"measure":"Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population)","timeFrame":"From Day 1 to Month 12.","effectByArm":[{"arm":"DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide","deltaMin":38,"sd":null},{"arm":"DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide","deltaMin":46,"sd":null},{"arm":"DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide","deltaMin":43,"sd":null},{"arm":"DS-TB: 2 Months HRZE / 4 Months HR","deltaMin":52,"sd":null},{"arm":"MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":26,"countries":["Georgia","Kenya","Malaysia","Philippines","South Africa","Tanzania","Uganda","Zambia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":65},"commonTop":["Hyperuricaemia","Arthralgia","Aspartate aminotransferase increased","Alanine aminotransferase increased","Blood uric acid increased"]}}